Dr. Gordon B. Mills on Moving Toward Patient-Specific Treatment in Breast Cancer
​Gordon B. Mills, MD, PhD, says individualized treatment, as opposed to treating patients solely based on their malignancy type, must happen in order to improve patient outcome.
Gordon B. Mills, MD, PhD, chair of Systems Biology, co-director of the Institute of Personalized Medicine, University of Texas MD Anderson Cancer Center, discusses the oncological trend of moving toward individually treating patients with breast cancer. Mills says this individualized treatment, as opposed to treating patients solely based on their malignancy type, must happen in order to improve patient outcome.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
